Document is current
Any future updates will be listed below
-
Authors
Gholizadeh, Elham
Zangene, Ehsan
Vadadokhau, Uladzislau
Ritz, Danilo https://orcid.org/0009-0004-8603-9754
Miettinen, Juho J. https://orcid.org/0000-0002-3987-1693
Soliymani, Rabah https://orcid.org/0000-0003-0184-3352
Baumann, Marc
Wilhelm, Mathias https://orcid.org/0000-0002-9224-3258
Kankuri, Esko https://orcid.org/0000-0002-2193-8773
Haynes, Paul A. https://orcid.org/0000-0003-1472-8249
Heckman, Caroline A. https://orcid.org/0000-0002-4324-8706
Saei, Amir A. https://orcid.org/0000-0002-2639-6328
Jafari, Mohieddin https://orcid.org/0000-0002-6991-8587
-
Funding
Funding for this research was provided by:
Academy of Finland (332454)
Jane ja Aatos Erkon Säätiö (220031)
Sigrid Juséliuksen Säätiö
Syöpäsäätiö (4709178)
Cancerfonden (243595 Pj)
Vetenskapsrådet (2023-02692)
Jeanssons Stiftelser (J2023-0094)
- License Information
-
More Information
Article History
Received: 14 August 2025
Accepted: 26 February 2026
First Online: 25 March 2026
Competing interests
: C.A.H has received research funding from KronosBio, Novartis, Oncopeptides, WNTResearch, and Zentalis Pharmaceuticals, plus personal fees from Amgen and Autolus, unrelated to this work. M.W. is a co-founder and shareholder of MSAID GmbH and a scientific advisor of Momentum Biotechnologies, but he has no operational role in either company. The remaining authors declare no competing interests.
